ArticlePloS one2012
Cytokinome profile of patients with type 2 diabetes and/or chronic hepatitis C infection.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Carnosine Supplementation Improves Serum Resistin Concentrations in Overweight or Obese Otherwise Healthy Adults: A Pilot Randomized Trial.Nutrients · 2018Trial
- Hostility is Associated with Interferon γ Inducible Protein 10 in Opioid Maintenance Treatment Patients with Chronic Hepatitis C.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2025Article
- Article
- Cytokines in hepatitis C-infected patients with or without opioid maintenance therapy.Acta neuropsychiatrica · 2024Article
- The Importance of CXCL1 in the Physiological State and in Noncancer Diseases of the Oral Cavity and Abdominal Organs.International journal of molecular sciences · 2022Review
- Ozone improved the wound healing in type 2 diabetics via down-regulation of IL- 8, 10 and induction of FGFR expression.Acta bio-medica : Atenei Parmensis · 2022Article
- The GEF Cytohesin-2/ARNO Mediates Resistin induced Phenotypic Switching in Vascular Smooth Muscle Cells.Scientific reports · 2020Article
- Systemic factors related to soluble (pro)renin receptor in plasma of patients with proliferative diabetic retinopathy.PloS one · 2017Article
- Diabetes-associated dysregulated cytokines and cancer.Integrative cancer science and therapeutics · 2016Article
- GPX4 and GPX7 over-expression in human hepatocellular carcinoma tissues.European journal of histochemistry : EJH · 2015Article
- Plasma levels of growth-related oncogene (CXCL1-3) associated with fibrosis and platelet counts in HCV-infected patients.Alimentary pharmacology & therapeutics · 2015Article
- The Cytokinome Profile in Patients with Hepatocellular Carcinoma and Type 2 Diabetes.PloS one · 2015Article
- Evaluation of the selenotranscriptome expression in two hepatocellular carcinoma cell lines.Analytical cellular pathology (Amsterdam) · 2015Article
- Cytokinome profile evaluation in patients with hepatitis C virus infection.World journal of gastroenterology · 2014Review
- The role of chemokines in acute and chronic hepatitis C infection.Cellular & molecular immunology · 2014Review
- Decreased serum level of miR-146a as sign of chronic inflammation in type 2 diabetic patients.PloS one · 2014Article
- Synergistic antitumor effect of Doxorubicin and tacrolimus (FK506) on hepatocellular carcinoma cell lines.TheScientificWorldJournal · 2014Article
- Diabetes and infections-hepatitis C: is there type 2 diabetes excess in hepatitis C infection?Current diabetes reports · 2013Review
- Prevalence of type 2 diabetes mellitus in hepatitis C virus infected population: a Southeast Asian study.Journal of diabetes research · 2013Article
- Oxidant status and lipid composition of erythrocyte membranes in patients with type 2 diabetes, chronic liver damage, and a combination of both pathologies.Oxidative medicine and cellular longevity · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Both type 2 diabetes (T2D) and chronic hepatitis C (CHC) infection are associated with increased risk of developing hepatocellular carcinoma (HCC). Cytokines are known to play an important role not only in the mechanisms of insulin resistance and glucose disposal defects but also in the pathological processes occurring in the liver during viral infection. We evaluated the serum levels of many cytokines, chemokines, adipokines and growth factors in patients with type 2 diabetes, CHC, CHC-related cirrhosis, CHC and type 2 diabetes and CHC-related cirrhosis and type 2 diabetes by BioPlex assay. The obtained data evidenced that the serum levels of some proteins are significantly up-regulated in all the patients or in those with only one disease and are often higher, even if in different amounts, when both diseases are associated. In particular, our results can be useful for the clinical monitoring of patients because they give specific information in regard to the progression from CHC to LC and CHD to LCD. Moreover, some molecules have shown significant correlations with clinical/biochemical data, suggesting the possibility to define mini-panels that can be used as specific markers for the different disease staging. However, our observations demonstrate that an integrated approach is much more powerful than isolated measurements to evaluate specific stages of these two complex pathologies (type 2 diabetes and chronic CHC hepatitis) alone or when they are concomitant in a patient. In fact it has emerged as an accurate, simple, specific, noninvasive, reproducible and less expensive method that, in future, could be included in routine clinical practice to monitor the association of type 2 diabetes and/or CHC to liver cirrhosis and, possibly, to cancer, and to improve the prognosis of these diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.